The project addresses a critical gap in the global pharmaceutical landscape: the speed and scalability of vaccine production for emerging threats. By focusing on pathogens with epidemic potential, especially high-risk viruses that could trigger the next international health crisis, the consortium aims to move beyond reactive measures. It wants to build a proactive, „plug-and-play“ vaccine infrastructure.
The Scope: Bridging the Gap Between Innovation and the Clinic
The scope of this Horizon Europe project is ambitious. It targets the technical hurdles that often stall vaccine candidates in the laboratory. By streamlining the development of novel platforms, including viral vectors and recombinant proteins, the project seeks to create a blueprint for rapid deployment. The expected outcomes include not only successful Phase 1/2 clinical candidates. The goal is a refined regulatory roadmap and standardized manufacturing processes that can be activated the moment a new threat is identified.
Central to this mission is the Austrian biotech firm Nuvonis Technologies, which has been invited as a key consortium partner for two distinct applications within the EU HORIZON framework. Nuvonis’s selection is a testament to the company’s specialized infrastructure and expertise, which has become a cornerstone for developers seeking to move from concept to clinic.
Nuvonis brings a „full-stack“ technical contribution to the consortium, centered on:
- Proprietary Cell Lines: Providing the essential biological "factories" needed to produce a high-titer vaccine.
- Regulatory Experience: Navigating the stringent EU and global pharmaceutical requirements to ensure safety and compliance from day one.
- CMC and MSAT Leadership: Offering proven expertise in Chemistry, Manufacturing, and Controls (CMC), alongside Manufacturing Science and Technology (MSAT) to ensure process consistency.
- Process Development: Refining production workflows to maximize yield while maintaining the highest purity standards.
A Statement from Leadership
For Nuvonis, this partnership represents the intersection of technical excellence and humanitarian purpose. Christina Nicolodi, CEO of Nuvonis, emphasized the weight of this responsibility:
„Participating in these Horizon Europe projects is more than a strategic milestone for Nuvonis; it is a commitment to global health security. Our expertise in navigating the complex regulatory and manufacturing pathways of novel therapeutics allows us to bridge the gap between innovation and the clinic. At Nuvonis, we are happy to make a change in the lives of people with unmet medical needs by ensuring that the next generation of vaccines is safe, scalable, and ready when the world needs them most.“
Strategic Relevance: EU, Global Health, and Nuvonis
The inclusion of Nuvonis in this Horizon Europe project carries three-fold significance:
- For the European Union: It reinforces the EU’s „Health Union“ strategy, keeping intellectual and manufacturing property for life-saving vaccines remains within European borders. This reduces dependency on external supply chains during crises.
- For Global Health: By focusing on „epidemic potential“ pathogens, the project contributes to the global „100-Day Mission“. This initiative aims to have a safe, effective vaccine ready for distribution within 100 days of a pandemic threat being identified.
- For Nuvonis: This role solidifies Nuvonis as a trusted partner in the international biotech ecosystem. It validates their cell-bank technology and manufacturing leadership on the world stage, positioning the company as an essential architect of tomorrow’s medical countermeasures.
As this Horizon Europe project moves forward, the synergy between public funding and private technical mastery, embodied by partners like Nuvonis, will be the deciding factor in whether the world is ready for the next „Disease X”.
Contact
Nuvonis Technologies GmbH
office(at)nuvonis.com